NCT03315364 2026-04-01OPTIMALDaehwa Pharmaceutical Co., Ltd.Phase 2/3 Active not recruiting549 enrolled
NCT02491632 2026-03-18Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced CancerM.D. Anderson Cancer CenterPhase 2/3 Active not recruiting90 enrolled 13 charts
NCT03021486 2026-03-18Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent CancerM.D. Anderson Cancer CenterPhase 2/3 Active not recruiting70 enrolled 20 charts
NCT02598661 2026-01-05Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Geron CorporationPhase 2/3 Active not recruiting289 enrolled 35 charts 2 FDA
NCT03743649 2025-12-26Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative CareM.D. Anderson Cancer CenterPhase 2/3 Active not recruiting110 enrolled